Semen News and Research

RSS

Semen is an organic fluid, also known as seminal fluid, that usually contains spermatozoa. It is secreted by the gonads (sexual glands) and other sexual organs of male or hermaphroditic animals and can fertilize female ova. The process of discharge is called ejaculation.

Age of sperm donor does not affect outcome in terms of live birth

Despite emerging evidence of a decline in sperm quality with increasing age, an analysis of every first fertility treatment cycle performed in the UK using sperm donation shows that outcome in terms of live birth is not affected by the age of the sperm donor.

30 Jun 2014

Study examines effect of phthalate exposure in humans’ sperm epigenetics

A new three-year, $440,000 study led by environmental health scientist Richard Pilsner at the University of Massachusetts Amherst is now underway to investigate whether phthalate levels in expectant fathers have an effect on the couples' reproductive success, via epigenetic modifications of sperm DNA.

12 Jun 2014

Certain molecules in seminal fluid indicate presence and severity of prostate cancer

Improved diagnosis and management of one of the most common cancers in men - prostate cancer - could result from research at the research at the University of Adelaide, which has discovered that seminal fluid (semen) contains biomarkers for the disease.

9 Jun 2014

Cannabis use affects size and shape of sperm in young men

Young men who use cannabis may be putting their fertility at risk by inadvertently affecting the size and shape of their sperm according to research published today (Thursday 5 June 2014).

5 Jun 2014

Men who feel stressed have fewer, slower sperm

Psychological stress is harmful to sperm and semen quality, affecting its concentration, appearance, and ability to fertilize an egg, according to a study led by researchers Columbia University's Mailman School of Public Health and Rutgers School of Public Health.

30 May 2014

Birth defects do not appear to be associated with father's semen quality, says study

Birth defects do not appear to be associated with the father's semen quality, according to a new study at the 109th Annual Scientific Meeting of the American Urological Association (AUA).

19 May 2014

Men with sperm abnormalities at increased risk of dying sooner, study finds

Men who are infertile because of defects in their semen appear to be at increased risk of dying sooner than men with normal semen, according to a study led by a researcher at the Stanford University School of Medicine.

16 May 2014

Study characterizes mechanisms of pathogenesis, transmission of bacteria that cause gonorrhea

Researchers have come a step closer to understanding how gonorrhea infections are transmitted. When Neisseria gonorrhoeae, the bacteria responsible for gonorrhea, are exposed to seminal plasma, the liquid part of semen containing secretions from the male genital tract, they can more easily move and start to colonize.

4 Mar 2014

New video tracking system could help select most viable sperm

To improve their chances of success, in vitro fertilization (IVF) clinics need to assess the viability of the sperm they use. Now doctors may soon have a new technique to help them sort the good sperm cells from the less viable ones: a tracking system, developed by a team of researchers from four European institutions, that takes 3-D movies of living sperm.

12 Feb 2014

Market research report on global and China insulin industry

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 382 million in 2013 at a compound annual growth rate of 7.6%.

12 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Shifts in zinc's location could be exploited for early diagnosis of prostate cancer

Zinc, an essential nutrient, is found in every tissue in the body. The vast majority of the metal ion is tightly bound to proteins, helping them to perform biological reactions. Tiny amounts of zinc, however, are only loosely bound, or "mobile," and thought to be critical for proper function in organs such as the brain, pancreas, and prostate gland. Yet the exact roles the ion plays in biological systems are unknown.

9 Dec 2013

Conceive Plus Fertility Personal Lubricant receives FDA approval

The Pew Research Center reports that in the year 2011, the birth rate in the United States slid by 8%. That kind of statistic would indicate getting pregnant isn't as easy as it used to be. However, pharmaceutical manufacturer SASMAR aims to be at the forefront of helping couples to start families. The FDA has officially approved their OTC sperm friendly fertility personal lubricant, Conceive Plus for sale in the US market.

15 Nov 2013

Researchers study potential role of two risk factors in preeclampsia

Although preeclampsia occurs in about 3 percent of pregnancies, it's still unforeseen in many cases. A report of new research, now in press at the Journal of Reproductive Immunology, documents how two distinct risk factors combine to affect the odds that a first-time mother could develop the sometimes life-threatening pregnancy complication.

11 Sep 2013

Frozen sperm taken by biopsy from testicles may help couples conceive through IVF

Frozen sperm taken by biopsy from testicles in men with no sperm in their semen is as effective as fresh sperm taken by biopsy in helping couples conceive through in vitro fertilization (IVF), according to a study at Washington University School of Medicine in St. Louis.

7 Aug 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Adverse fetal growth, exposure to maternal smoking correlated with lower measures of sperm quality

Studies over the past 20 years have suggested (though not unequivocally confirmed) that semen quality is in decline, reflected most evidently in falling sperm counts and reduced sperm motility.

8 Jul 2013

Risk of implantation failure, lower yield of oocytes linked to higher levels of urinary phthalates

Phthalates are among a group of industrial chemicals shown in some studies to have adverse effects on reproductive health and development, particularly in the male. As such, they have been collectively defined as "endocrine disruptors", and proposed as one of several possible environmental exposures responsible for a decline in fertility.